Loading
Life sciences · Journal article
International Journal of Progressive Research in Engineering Management and Science · August 5, 2026
Raises a question worth testing. It does not answer one.
This is a methodological simulation study presenting a transparent framework for integrating WGS-derived variables with phenotypic drug-susceptibility results to prioritize candidate antimicrobial-resistance variants in M. tuberculosis. Using 200 synthetic isolate records, the authors demonstrate an analytical workflow and identify evidence gaps needed for future empirical investigations, but present no empirical discoveries or validated resistance determinants.
Methodological simulation study with synthetic data. Hypothetical M. tuberculosis isolates in a Nigerian context; no patients, clinical specimens, cultures, raw sequence reads or sequencing runs were involved.. Intervention: Integration of WGS-derived variables with phenotypic drug-susceptibility results using prespecified prioritisation rules to evaluate resistance prediction and prioritise candidate antimicrobial-resistance variants. n = 200. Nigeria-focused methodological framework.
Within the synthetic scenario, genotype-phenotype agreement was highest for rifampicin, isoniazid, fluoroquinolones and amikacin and lower for ethambutol and pyrazinamide Lineage 4 was the predominant assigned lineage, while Lineage 2 was configured to occur more frequently with advanced resistance Application of prespecified prioritisation rules retained five hypothetical candidate variants, described as not empirical discoveries or validated resistance determinants
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This framework is intended to guide the design of future multicentre Nigerian genomic-surveillance studies rather than provide immediate clinical guidance. Clinicians should note that the synthetic outputs do not represent population-level estimates or biological findings and should await empirical validation with real isolates, raw-read data, and functional studies.
A simulation-based methodological framework using synthetic data to explore analytical workflows for WGS-based resistance prediction; no empirical findings or validated discoveries are presented.
As stated by the source record.
Quoted from the source exactly as published.
This framework is intended to guide the design of future multicentre Nigerian genomic-surveillance studies rather than provide immediate clinical guidance. Clinicians should note that the synthetic outputs do not represent population-level estimates or biological findings and should await empirical validation with real isolates, raw-read data, and functional studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Tuberculosis remains a major cause of infectious-disease mortality, and drug-resistant disease continues to undermine treatment and control programmes.Whole-genome sequencing (WGS) can provide comprehensive information on established resistance mutations, bacterial lineages and potential transmission clusters, but variants absent from validated catalogues require cautious interpretation, particularly where African genomes and linked phenotypic data are underrepresented.This paper presents a transparent simulation-based framework showing how WGS-derived variables can be integrated with phenotypic drug-susceptibility results to evaluate resistance prediction and prioritise candidate antimicrobial-resistance variants in a Nigerian context.A deterministic synthetic scenario representing 200 non-duplicate hypothetical Mycobacterium tuberculosis isolate records was constructed from prespecified marginal totals.No patients, clinical specimens, cultures, raw sequence reads or sequencing runs were involved.The scenario included demographic and geographical variables, resistance phenotypes, sequencing-quality indicators, lineage assignments, recognised resistance mutations and deliberately introduced unclassified variants.Descriptive analysis, genotype-phenotype agreement measures, logistic-regression illustration and simulated phylogenetic clustering were used to demonstrate an analytical workflow.Within the constructed scenario, agreement was highest for rifampicin, isoniazid, fluoroquinolones and amikacin and lower for ethambutol and pyrazinamide.Lineage 4 was the predominant assigned lineage, while Lineage 2 was configured to occur more frequently with advanced resistance.Application of prespecified prioritisation rules retained five hypothetical candidate variants; these are not empirical discoveries or validated resistance determinants.The framework demonstrates reporting logic for future empirical WGS investigations and identifies the additional evidence required for causal and clinical interpretation, including actual isolates, raw-read provenance, minimum inhibitory concentrations, population-structure correction, independent replication and functional validation.Its principal contribution is methodological: it provides a structured model for designing multicentre Nigerian genomic-surveillance studies without presenting synthetic outputs as population estimates or biological findings.